Recombinant <i>Myxoma Virus</i>-Derived Immune Modulator M-T7 Accelerates Cutaneous Wound Healing and Improves Tissue Remodeling.

Pharmaceutics · 2020 · PMC7690590 · PMID 33105865

Europe PMC DOI

hedged sentence

0.0763

closest p · 1.5× alpha

0.0763

boldest claim

The sentences

approached significancep = 0.0763so close (0.05 < p ≤ 0.1)

Wounds treated with M-T7 had an elevated level of CCL2 on day 4 post-wounding, which approached significance ( p = 0.0763), while levels of CCL2 were not different between saline and M-T7 treatment on days 1 and 7 post-wounding.

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.